December 01, 2015
2 min read
Save

Five recent developments in breast surgery

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Recent developments reported on Healio.com/Aesthetics have included study results showing that optimal primary treatment for breast implant-associated anaplastic large cell lymphoma was definitive surgery with implant removal and total capsulectomy.

Other developments included a proposed identification system for challenging breast augmentations and a systematic review of studies suggesting there is inconclusive evidence about any association between silicone gel breast implants and long-term health outcomes

Breast implant-associated anaplastic large cell lymphoma treated with definitive surgery

Optimal primary treatment for breast implant-associated anaplastic large cell lymphoma was definitive surgery with implant removal and total capsulectomy, according to research presented at the American Society of Plastic Surgery’s annual meeting in Boston.

Researchers conducted a retrospective review of all published cases from 1997 to 2015 and unpublished cases at M.D. Anderson Cancer Center of breast implant-associated anaplastic large cell lymphoma.  Read more

Identification system proposed for challenging breast augmentations

Researchers defined complicating factors for breast augmentation surgery, and suggested an identification system for preoperative identification of breast deformities in a recently published study.

The researchers conducted a retrospective analysis of photographs and records of 100 women (average age, 26 years) who underwent breast augmentation, with an average follow-up of 18 months. Read more

Evidence for association between silicone gel breast implants, long-term health outcomes inconclusive

Results from a systematic review of studies suggest there is inconclusive evidence about any association between silicone gel breast implants and long-term health outcomes.

The FDA removed silicone gel breast implants from the U.S. market for cosmetic use in 1992 due to safety concerns. The implants were reintroduced in 2006 after FDA approval. Read more

Contoured cohesive gel breast implants by three manufacturers comparable

Contoured cohesive gel breast implants by three different manufacturers were found to have similar low complication rates and high satisfaction rates during a 10-year period, according to recently published study results.

Researchers conducted a prospective study of 695 patients (mean age 42.7 years) who underwent breast implantation with contoured cohesive silicone gel breast implants performed by a single surgeon. Read more

Natrelle 410 extra-full projection silicone implants had low 2-year complication risk

Women undergoing breast reconstruction with Natrelle 410 silicone gel extra-full projection implants following mastectomy had a low risk of complications at 2 years, according to study results.

Researchers studied 2,795 women (median age, 50 years) who received at least one Natrelle Style 410 highly-cohesive silicone gel extra-full projection implant (Allergan) after mastectomy in two prospective, multicenter trials.  Read more